By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genmab A/S 

Toldbodgade 33

Copenhagen    K-1253  Denmark
Phone: 45-7020-2728 Fax: 45-7020-2729


Key Statistics

Ownership: Public

Web Site: Genmab A/S
Symbol: GEN.CO



Bionomics Limited  Anti-angiogenesis therapeutic antibody development

Company News
Genmab A/S (GEN.CO) Announces Phase III Studies Of Ofatumumab In Relapsing Multiple Sclerosis 6/2/2016 8:25:19 AM
Genmab A/S (GEN.CO) Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 5/19/2016 6:47:18 AM
Genmab A/S (GEN.CO) Announces Daratumumab Data To Be Presented At 2016 ASCO Annual Meeting 4/20/2016 10:44:01 AM
MorphoSys AG Sues Janssen Biotech Inc. (JNJ) And Genmab A/S (GEN.CO) For Patent Infringement 4/4/2016 11:46:30 AM
Genmab A/S (GEN.CO) Release: CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) For Relapsed And Refractory Multiple Myeloma 4/1/2016 12:57:12 PM
Genmab A/S (GEN.CO) Release: Major Shareholder Announcement 2/5/2016 7:31:11 AM
Genmab A/S (GEN.CO) Announces FDA Approval Of DARZALEX (Daratumumab) For Multiple Myeloma And Updates Financial Guidance 11/17/2015 7:57:43 AM
Genmab A/S (GEN.CO) Release: Major Shareholder Announcement 9/30/2015 8:00:11 AM
Genmab A/S (GEN.CO) Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients 8/27/2015 7:16:19 AM
Genmab A/S (GEN.CO) Announces Completion Of Rolling Submission Of Biologics License Application For Daratumumab In Multiple Myeloma And Achievement Of A USD 15 Million Milestone 7/10/2015 6:54:39 AM